Sber is developing a platform to integrate artificial intelligence (AI) into pharmaceutical development processes, the bank’s president, Herman Gref, stated during the online conference Made in Sber. He noted the development is being carried out in collaboration with representatives from the biopharmaceutical industry.
“Artificial intelligence assists with molecular modeling and helps eliminate the most costly dead-end stages,” he said. “For instance, the combined application of AI, genetic technologies, and bioinformatics can reduce drug development timelines for cancer therapies to as little as two years,” Gref remarked (as reported by TASS).
The conference also featured the bank’s plans for financing generative AI technologies. Overall, over a three-year period including 2026, Sberbank intends to invest around 600 billion rubles ($6.5 billion) in this area, with the bulk of the funding allocated for the coming year.
Previously, Sberbank introduced an AI-driven solution designed to optimize medication supply for cancer care facilities. The system forecasts disease incidence rates for specific conditions and, based on this data, calculates the required annual volume of pharmaceuticals.